Spevigo (spesolimab-sbzo)
- Drug Name: Spevigo
- Generic Name: Spesolimab-sbzo
- Dosage Forms and Strengths: Spevigo is available in an injectable form, supplied as a 450 mg/7.5 mL (60 mg/mL) solution in a single-dose vial. This specific formulation is designed to ensure ease of use and accurate dosing.
- Manufactured by: Boehringer Ingelheim Pharmaceuticals, Inc.
The drug SPEVIGO is categorized as an antagonist of the interleukin-36 receptor. It is intended primarily to treat adult patients’ flare-ups of generalized pustular psoriasis. With SPEVIGO, this condition—which is marked by severe and recurrent skin inflammation—can be properly controlled.
Dosage and Administration:
- It is recommended that SPEVIGO be supplied intravenously as a single 900 mg dose; this procedure usually takes around 90 minutes to finish.
- One week after the first injection, a follow-up intravenous dose of 900 mg might be taken into consideration if flare symptoms are still present.
- Before using SPEVIGO, it must be diluted. The complete prescription information contains detailed directions for preparing, administering, and storing the diluted solution.
- Infections Risk: The use of SPEVIGO may increase susceptibility to infections. Avoid initiating SPEVIGO treatment during clinically significant active infections. Patients should be vigilant for signs of infection and seek prompt medical attention if symptoms arise post-treatment.
- Tuberculosis Evaluation: Prior to commencing SPEVIGO treatment, patients must undergo a thorough evaluation for tuberculosis (TB). This precautionary step is crucial to ensure the overall safety and health of the patient.
- Hypersensitivity and Infusion Reactions: SPEVIGO use may lead to hypersensitivity reactions, including Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), as well as infusion-related reactions. Immediate discontinuation of SPEVIGO is imperative in case of serious hypersensitivity reactions, followed by appropriate medical intervention.
- Vaccination Precaution: Simultaneous administration of live vaccines with SPEVIGO is not recommended. This precautionary measure aims to prevent potential interactions and complications that may arise from concurrent vaccination.
If you are considering the import of Spevigo (spesolimab-sbzo) to India, please be aware that Daxxify can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:
Required Documentation for Import:
- A valid prescription from a qualified medical practitioner.
- Diagnostic reports of the patient.
- Government-issued identification proof for the patient, as recognized by the Government of India.
The order for Spevigo (spesolimab-sbzo) will be confirmed upon the receipt of the following documents:
- A valid prescription from a qualified doctor.
- An import permit, if applicable.
Daxxify (daxibotulinumtoxinA-lanm) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.
Spevigo can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.
IPN (Indian Pharma Network) is dedicated to facilitating the supply ofSpevigo (spesolimab-sbzo) to locations both within India and worldwide, while adhering to relevant legal requirements.
Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.
Indian Pharma Network is proficient in sourcingSpevigo (spesolimab-sbzo) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.